{"id":390533,"date":"2018-12-06T00:00:00","date_gmt":"2018-12-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0002-2018-biopharma-axial-spondyloarthritis-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-04-22T05:24:46","modified_gmt":"2026-04-22T05:24:46","slug":"dlsfim0002-2018-biopharma-axial-spondyloarthritis-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0002-2018-biopharma-axial-spondyloarthritis-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Axial Spondyloarthritis | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p>The treatment of axial spondyloarthritis has been transformed in the last decade by the approval of biologics to treat the disease and the recognition that patients without evidence of radiographic damage can be treated, along with the patients who have definitive ankylosing spondylitis. The result has been a\u00a0billion-dollar\u00a0market in the seven major pharmaceutical markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). A new wave of change is slated to come to the market, as drugs with new mechanisms of action are approved and as regulatory authorities clear the way for biologics to treat nr-<abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr>\u00a0in the major markets<\/p>\n","protected":false},"template":"","class_list":["post-390533","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ankylosing-spondylitis","biopharma-therapy-areas-axial-spondyloarthritis","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390533\/revisions"}],"predecessor-version":[{"id":393657,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390533\/revisions\/393657"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}